Trial Outcomes & Findings for Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses (NCT NCT02189863)
NCT ID: NCT02189863
Last Updated: 2016-02-18
Results Overview
Driving reaction time to hazards was assessed during simulated night time driving and measured as time to brake, in seconds. One eye (study eye) contributed to the analysis. This outcome measure was prespecified for AOAMV and AOAMF.
COMPLETED
NA
33 participants
Week 2, each period
2016-02-18
Participant Flow
Subjects were recruited from 2 investigational sites located in the UK.
Of the 33 enrolled, 6 participants were exited as screen failures prior to randomization. This reporting group includes all randomized participants who successfully tried at least one study lens (27).
Participant milestones
| Measure |
AOAMV, Then AOAMF
Lotrafilcon B MV contact lenses (AOAMV) worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses (AOAMF) worn for 2 weeks in Period 2
|
AOAMF, Then AOAMV
Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
|
|---|---|---|
|
First 2 Weeks
STARTED
|
12
|
15
|
|
First 2 Weeks
COMPLETED
|
8
|
13
|
|
First 2 Weeks
NOT COMPLETED
|
4
|
2
|
|
Second 2 Weeks
STARTED
|
8
|
13
|
|
Second 2 Weeks
COMPLETED
|
8
|
13
|
|
Second 2 Weeks
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
| Measure |
AOAMV, Then AOAMF
Lotrafilcon B MV contact lenses (AOAMV) worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses (AOAMF) worn for 2 weeks in Period 2
|
AOAMF, Then AOAMV
Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
|
|---|---|---|
|
First 2 Weeks
Motion Sickness
|
4
|
2
|
Baseline Characteristics
Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses
Baseline characteristics by cohort
| Measure |
Overall
n=27 Participants
Lotrafilcon B MV and lotrafilcon B MF contact lenses worn in Period 1 and Period 2, as randomized
|
|---|---|
|
Age, Continuous
|
55.4 years
STANDARD_DEVIATION 5.4 • n=5 Participants
|
|
Sex: Female, Male
Female
|
17 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Week 2, each periodPopulation: This analysis population includes all randomized subjects in the groups to which they were randomly assigned who successfully completed both study lens follow-up evaluations without a protocol deviation that was documented as impacting the assessment of the hypotheses (Per-Protocol).
Driving reaction time to hazards was assessed during simulated night time driving and measured as time to brake, in seconds. One eye (study eye) contributed to the analysis. This outcome measure was prespecified for AOAMV and AOAMF.
Outcome measures
| Measure |
AOAMV
n=21 Participants
Lotrafilcon B spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near for 2 weeks
|
AOAMF
n=21 Participants
Lotrafilcon B multifocal contact lenses worn in both eyes for 2 weeks
|
|---|---|---|
|
Driving Reaction Time to Hazards (as Measured by Time to Brake, in Seconds)
|
1.89 seconds
Standard Deviation 0.22
|
1.88 seconds
Standard Deviation 0.19
|
SECONDARY outcome
Timeframe: Week 2, each periodPopulation: This analysis population includes all randomized subjects in the groups to which they were randomly assigned who successfully completed both study lens follow-up evaluations without a protocol deviation that was documented as impacting the assessment of the hypotheses (Per-Protocol).
The standard deviation of lateral positioning (staying in the lane) was assessed during simulated night time driving and measured as the distance of deviation from the reference point, in meters. This outcome measure is prespecified for AOAMV and AOAMF.
Outcome measures
| Measure |
AOAMV
n=21 Participants
Lotrafilcon B spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near for 2 weeks
|
AOAMF
n=21 Participants
Lotrafilcon B multifocal contact lenses worn in both eyes for 2 weeks
|
|---|---|---|
|
Standard Deviation of Lateral Positioning
|
0.35 meters
Standard Deviation 0.06
|
0.35 meters
Standard Deviation 0.05
|
Adverse Events
AOAMV
AOAMF
Lotra B SVD
Biofinity MF
Habitual
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
AOAMV
n=25 participants at risk
Lotrafilcon B spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near for 2 weeks
|
AOAMF
n=23 participants at risk
Lotrafilcon B multifocal contact lenses worn in both eyes for 2 weeks
|
Lotra B SVD
n=23 participants at risk
Lotrafilcon B spherical contact lenses worn with both eyes corrected for distance during Period 1 for a same-day assessment
|
Biofinity MF
n=21 participants at risk
Comfilcon A multifocal contact lenses worn in both eyes during Period 2 for a same-day assessment
|
Habitual
n=27 participants at risk
Contact lenses worn in both eyes per subject's habitual prescription on Day 1, Period 1, for a same-day assessment
|
|---|---|---|---|---|---|
|
General disorders
Motion sickness
|
4.0%
1/25 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
|
4.3%
1/23 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
|
8.7%
2/23 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
|
0.00%
0/21 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
|
7.4%
2/27 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
|
Additional Information
Global Brand Lead, Global Medical Affairs, Vision Care
Alcon Research, Ltd.
Results disclosure agreements
- Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
- Publication restrictions are in place
Restriction type: OTHER